Form 4: Cingulate Inc. Executive Acquires 1,000 Stock Options

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reports the acquisition of 1,000 stock options on June 28, 2024.

Summary

• On June 28, 2024, Matthew Brams, the EVP and Chief Medical Officer of Cingulate Inc., acquired 1,000 stock options.
• The options have an exercise price of $0.32.
• The options were granted pursuant to the terms of Mr. Brams' Employment Agreement, as amended.
• The options are exercisable from June 28, 2024, and expire on June 28, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to an executive. While stock options can be seen as a positive incentive, this filing itself doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Management Comments

• The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation packages.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, potentially incentivizing them to increase shareholder value.

Key Dates

Keywords

stock options, Cingulate Inc., Matthew Brams, EVP, Chief Medical Officer, Form 4, insider trading